Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary

William B Feldman; Benjamin N Rome; Lisa Soleymani Lehmann; Aaron S Kesselheim

doi:10.1001/jamainternmed.2019.7018

Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary

JAMA Intern Med. 2020 Apr 1;180(4):597-601. doi: 10.1001/jamainternmed.2019.7018.

Authors

William B Feldman^{1

2

3}, Benjamin N Rome^{1

3}, Lisa Soleymani Lehmann^{3

4

5}, Aaron S Kesselheim^{1

3}

Affiliations

¹ Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ US Department of Veteran Affairs, New England Healthcare System, Boston, Massachusetts.
⁵ Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Abstract

This economic evaluation estimates insulin savings that would result if Medicare Part D used US Department of Veterans Affairs–negotiated prices and the Veterans Affairs formulary for patients with diabetes.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus / drug therapy*
Diabetes Mellitus / epidemiology
Drug Prescriptions / economics
Formularies as Topic
Humans
Hypoglycemic Agents / economics*
Insulin / economics*
Insurance Benefits / economics
Medicare Part D / economics*
United States / epidemiology
United States Department of Veterans Affairs*

Substances

Hypoglycemic Agents
Insulin

Grants and funding

T32 HL007633/HL/NHLBI NIH HHS/United States